ATRA - חוב כולל להון Atara Bio

The price visualization on GURU.Markets demonstrates the total debt-to-equity ratio of Atara Biotherapeutics (ATRA), which stands at 0.00. Atara Biotherapeutics (ATRA) leads in allogeneic T-cell therapy, offering off-the-shelf Ebvallo products to combat cancer. Production automation and AI-driven molecular design are accelerating processes, although medicine remains personalized. Revenue growth in Europe and expected new treatment indications support the asset's potential.

Atara Biotherapeutics faces high cash flow volatility and significant operating expenses during the commercialization phase of its cell products. This indicator compares total liabilities to net assets to determine the extent of the business's reliance on borrowed funds; therefore, an increase in the total debt-to-equity ratio signals rising financial risks in the absence of stable earnings.